Serum Institute gets expert panel nod to phase 2, 3 trial of Covovax for 2-17 years old
New Delhi: An expert panel of India's Central Drug Authority on Tuesday recommended granting permission to Serum Institute of India for conducting phase 2/3 trials of Covid vaccine Covovax on kids aged 2 to 17 years with certain conditions, official sources said.
The trials would cover 920 children, 460 each in the age-group of 12-17 and 2-11 across 10 sites.
Read also: First batch of COVID vaccine Covovax being manufactured at Pune facility: Serum Institute CEO
"The Subject Expert Committee on Covid-19 deliberated on the revised study protocol application given by SII on Tuesday and recommended granting permission to the firm for conducting phase 2/3 trial of Covovax on kids aged 2 to 17 years," a source said.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.